|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considering the elevated deposition of fibronectin (FN) in early atherosclerotic plaques and the close correlation between the vascular stiffness and the progression of atherosclerosis, we utilized FN coated hydrogels with increased stiffness for endothelial substrates within the microchannels.
|
31565711 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fibronectin in the vascular wall promotes inflammatory activation of the endothelium during vascular remodeling and atherosclerosis.
|
31408443 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that there are favourable conditions for FN matrix assembly by ECs in early atherosclerosis rather than at advanced stages.
|
30813060 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extra domain B of fibronectin (FN-EDB) is upregulated in the extracellular matrix during tissue remodeling and has been postulated as a potential biomarker for atherosclerosis, yet no systematic test for FN-EDB in plaques has been reported.
|
30613278 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibronectin in endothelial basement membranes promotes endothelial inflammatory activation and atherosclerosis but also promotes plaque stability and vascular remodeling.
|
29382667 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report the identification of isoDGR motifs in human atherosclerotic plaque components including extracellular matrix (ECM) proteins fibronectin and tenascin C, which have been strongly implicated in human atherosclerosis.
|
28720870 |
2017 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4.
|
26427793 |
2015 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Streptozotocin-induced diabetes in atherosclerosis-prone ApoE knockout mice promoted transitional matrix expression (fibronectin, thrombospondin-1) and deposition in intima of the aortic arch as determined by qRT-PCR array and immunohistochemistry.
|
24468139 |
2014 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present review discusses the substrates of FXIIIa (activated FXIII) involved in thrombosis and wound healing with a particular focus on: (i) the influence of plasma FXIIIa on the formation of stable fibrin clots able to withstand mechanical and enzymatic breakdown through fibrin-fibrin cross-linking and cross-linking of fibrinolysis inhibitors, in particular α2-antiplasmin; (ii) the role of intracellular FXIIIa in clot retraction through cross-linking of platelet cytoskeleton proteins, including actin, myosin, filamin and vinculin; (iii) the role of intracellular FXIIIa in cross-linking the cytoplasmic tails of monocyte AT1Rs (angiotensin type 1 receptors) and potential effects on the development of atherosclerosis; and (iv) the role of FXIIIa on matrix deposition and tissue repair, including cross-linking of extracellular matrix proteins, such as fibronectin, collagen and von Willebrand factor, and the effects on matrix deposition and cell-matrix interactions.
|
23075332 |
2013 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results demonstrate that while FN worsens the course of atherosclerosis by increasing the atherogenic plaque area, it promotes the formation of the protective fibrous cap, which in humans prevents plaques rupture and vascular occlusion.
|
22514136 |
2012 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data reveal novel constitutive activation of the endothelial β-catenin/TCF signaling pathway in atherosclerosis and regulation of fibronectin through hemodynamic shear stress.
|
21527747 |
2011 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The extracellular matrix protein fibronectin (FN) is focally deposited in regions of atherosclerosis, where it contributes to inflammatory signaling.
|
20378855 |
2010 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study demonstrates that plaque NIRF imaging is feasible with a novel single chain antibody and that ED-B expression is closely associated with inflammation in experimental atherosclerosis.
|
17468934 |
2007 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates that plaque NIRF imaging is feasible with a novel single chain antibody and that ED-B expression is closely associated with inflammation in experimental atherosclerosis.
|
17468934 |
2007 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Large amounts of fibronectin have been detected in atherosclerotic plaques, suggesting that it may play a role in the pathogenesis of atherosclerosis.
|
16375583 |
2006 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis.
|
14976060 |
2004 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As fibronectin and alpha5beta1 levels are augmented in vivo in the atherosclerotic plaques, these findings support the use of integrin antagonists as potential adjuvants in atherosclerosis treatment.
|
11166770 |
2001 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lp(a) has a great tendency to aggregate and bind to glucosaminoglycans, fibrin and fibronectin and is preferentially retained in the extracellular matrix during development of atherosclerosis and is in vitro phagocytosed by macrophages, probably as small aggregates.
|
9098440 |
1994 |